Tratamiento farmacológico de aneurismas de la aorta abdominal
Keywords:
aneurysm, inflammation, elastases, statinsAbstract
Abdominal aortic aneurysm (aaa) is a progressive dilation located in the abdominal aorta that is associated with a high mortality rate. The pathophysiology is complex because it involves mechanisms that culminate in a destruction of the middle layer from the aorta, loss of collagen fibers, and an inflammatory infiltrate that further aggravates the process. It is necessary to develop a pharmacological treatment that demonstrates prevention of the expansion and, therefore, the rupture of the aaa. Currently, there are some drugs which have shown to be beneficial; however, there is not enough evidence to prove their effectiveness. Research on the molecular mechanisms of its pathophysiology has allowed the development of novel drugs with promising results in animal models; however, it is necessary to expand research on these new therapeutic targets.
Downloads
References
Sakalihasan, N., Michel, J., Katsargyris, A., Kuivaniemi, H., Defraigne, J., & Nchimi, A. Abdominal Aortic Aneurysm. Nat. Rev. Dis. Prim.,2018; 4: 4-34.
Blum, G., Leucona, N., Mijangos, F., Olivares, S., Muñoz, R., & Ziga,
A. Propuesta de algoritmo diagnóstico de aneurisma de aorta abdominal con laboratorio vascular no invasivo en el Servicio de Angiología del Hospital General de México. Rev. Mex. Angiol., 2019; 47: 8-20.
Chaikof, E. L., Dalman, R. L., Eskandari, M. K., Jackson, B. M., Lee, W. A., Mansour, M. A. et al. The Society for Vascular Surgery Practice Guidelines on the Care of Patients with an Abdominal Aortic
Aneurysm. J. Vasc. Surg., 2018; 67: 2-77. https://doi.org/10.1016/j.jvs.2017.10.044
Kuivaniemi, H., Ryer, E. J., Elmore, J. R., & Tromp, G. Understanding the Pathogenesis of Abdominal Aortic Aneurysms. Expert Rev. Cardiovasc. Ther., 2015; 13: 975-987.
Zhang, S. L., Du, X., Chen, Y. Q., Tan, Y. S., & Liu, L. Potential Medication Treatment According to Pathological Mechanisms in Abdominal Aortic Aneurysm. J. Cardiovasc. Pharmacol., 2018; 71: 46-57.
Wang, Y., Liu, Z., Ren, J., & Xiang, M.-X. Pharmacological Therapy of Abdominal Aortic Aneurysm: An Update. Curr. Vasc. Pharmacol., 2017; 16: 114-124.
Oesterle, A., Laufs, U., & Liao, J. K. Pleiotropic Effects of Statins on the Cardiovascular System. Circ. Res., 2017; 120: 229-243.
Li, Y., Lu, G., Sun, D., Zuo, H., Wang, D. W., & Yan, J. Inhibition of Endoplasmic Reticulum Stress Signaling Pathway: A New Mechanism of Statins to Suppress the Development of Abdominal Aortic Aneurysm. plos One, 2017; 12: 1-19.
Zhang, W., Liu, Z., & Liu, C. Effect of Lipid-modifying Therapy on Long-term Mortality after Abdominal Aortic Aneurysm Repair: A Systemic Review and Meta-analysis. World J. Surg., 2015; 39: 794-801.
Kim, W., Gandhi, R. T., Peña, C. S., Herrera, R. E., Schernthaner, M. B., Acuña, J. M. et al. Influence of Statin Therapy on Aneurysm Sac Regression after Endovascular Aortic Repair. J. Vasc. Interv. Radiol.,2017; 28: 35-43. http://dx.doi.org/10.1016/j.jvir.2016.09.010
Salata, K., Syed, M., Hussain, M. A., De Mestral, C., Greco, E., Mamdani, M. et al. Statins Reduce Abdominal Aortic Aneurysm Growth, Rupture, and Perioperative Mortality: A Systematic Review and MetaAnalysis. J. Am. Heart Assoc., 2018; 7.
Blanchard, J. F., Armenian, H. K., Peeling, R., Friesen, P. P., Shen, C.,& Brunham, R. C. The Relation between Chlamydia pneumoniae Infection and Abdominal Aortic Aneurysm: Case-control Study. Clin. Infect.Dis., 2000; 30: 946-947.
Fields, G. B. The Rebirth of Matrix Metalloproteinase Inhibitors:Moving Beyond the Dogma. Cells, 2019; 8: 984.
Kroon, A. M., & Taanman, J. W. Clonal Expansion of T Cells inAbdominal Aortic Aneurysm: A Role for Doxycycline as Drug of Choice? Int. J. Mol. Sci., 2015; 16: 1178-1195.
Arnoud, M., Stijnrn, T., Waar, M., Hamming, J., Van Bockel, H., &
Lindeman, J. Original Research Doxycycline for Stabilization of Abdominal Aortic Aneurysms. Ann. Intern. Med., 2017; 159: 815-823.
Golledge, J., Moxon, J. V., Singh, T. P., Bown, M. J., Mani, K., & Wanhainen, A. Lack of an Effective Drug Therapy for Abdominal Aortic Aneurysm. J. Intern. Med., 2020; 288: 6-22.
Wemmelund, H., Hundborg, H., Johnsen, S., & Lindholt, J. Preadmission Use of Renin–Angiotensin Blockers and Rupture of Abdominal Aortic Aneurysm: A Nationwide, Population-based Study. Pharmacoepidemiol. Drug Saf., 2015; 25: 141-150.
Salata, K., Syed, M., Hussain, M. A., Eikelboom, R., De Mestral, C., Verma, S. et al. Renin-Angiotensin System Blockade Does Not Attenuate Abdominal Aortic Aneurysm Growth, Rupture Rate, or Perioperative Mortality after Elective Repair. J. Vasc. Surg., 2018; 67: 629-636. https://doi.org/10.1016/j.jvs.2017.09.007
Bicknell, C., Kiru, G., Falaschetti, E., & Powell, N. An Evaluation of the Effect of An Angiotensin-converting Enzyme Inhibitor on the Growth Rate of Small Abdominal Aortic Aneurysms: A Randomized Placebo-controlled Trial (aardvark). Eur. Heart J., 2016; 37: 3213-
Kristensen, K. E., Torp-Pedersen, C., Gislason, G. H., Egfjord, M., Rasmussen, H. B., & Hansen, P. R. Angiotensin-converting Enzyme Inhibitors and Angiotensin ii Receptor Blockers in Patients with Abdominal Aortic Aneurysms: Nation-wide Cohort Study. Arterioscler. Thromb. Vasc. Biol., 2015; 35: 733-740.
Merashli, M., Eid R., E. I., & Uthman, I. A Review of Current Management of Vasculo-Behcet’s. Curr. Opin. Rheumatol., 2018; 30: 50-56.
Movahedi, M., Beauchamp, M., Abrahamiwucz, M., Michau, L., Dixon, W., & Ray, D. Risk of Incident Diabetes Mellitus Associated with the Dosage and Duration of Oral Glucocorticoid Therapy in Patients with Rheumatoid Arthritis. Arthritis Rheumatol., 2016; 68:
-1098.
Tajima, Y., Goto, H., Ohara, M., Hashimoto, M., Akamatsu, D.,Shimizu, T. et al. Oral Steroid Use and Abdominal Aortic Aneurysm Expansion—Positive Association. Circ. J., 2017; 81: 1774-1782.
Kritikou, E., Kuiper, J., & Kovanen, P. T. Bot i. The Impact of Mast Cells on Cardiovascular Diseases. Eur. J. Pharmacol., 2016; 778: 103-115. http://dx.doi.org/10.1016/j.ejphar.2015.04.050
Gao, R., Liu, D., Guo, W., Ge, W., Fan, T., Li, B. et al. Meprin-(Mep1a) Enhances tnf-a Secretion by Mast Cells and Aggravates Abdominal Aortic Aneurysms. Br. J. Pharmacol., 2020; 177: 2872-2885.
Sillesen, H., Eldrup, N., Hultgren, R., Lindeman, J., Bredahl, K.,Thompson, M. et al. Randomized Clinical Trial of Mast Cell Inhibition in Patients with a Medium-sized Abdominal Aortic Aneurysm. Br. J.Surg., 2015; 102: 894-901.
Cameron, S. J., Russell, H. M., & Phillip Owens, A. Antithrombotic Therapy in Abdominal Aortic Aneurysm: Beneficial or Detrimental? Blood, 2018; 132: 2619-2628.
Owens, P., Edwards, T., Antoniak, S., Geddings, E., Jahangir, E., Denny, J. et al. Platelet Inhibitors Reduce Rupture in a Mouse Model of Established Abdominal Aortic Aneurysm. Arter. Thromb. Vasc. Biol.,2015; 35: 2032-2041.
Courtis, A., Makrygiannis, G., Cheramy-Bien, J., Purnelle, A., Pirotte, B., Dogne, J. et al. Therapeutic Applications of Prostaglandins and Thromboxane a2 Inhibitors in Abdominal Aortic Aneurysms. Curr.Drug Targ., 2018; 19: 1247-1255.
Wanhainen, A., Mani, K., Kullberg, J., Svensjö, S., Bersztel, A., Karlsson, L. et al. The Effect of Ticagrelor on Growth of Small Abdominal Aortic Aneurysms-A Randomized Controlled Trial. Cardiovasc. Res.,2020; 116: 450-456.
Sénémaus, J., Caligiuri, G., Etienne, H., Delbosc, S., Michel, J., & Coscas, R. Translational Relevance and Recent Advances of Animal Models of Abdominal Aortic Aneurysm. Arterioscler. Thromb. Vascilar Biol., 2017; 37: 401-410.
Lysgaard Poulsen, J., Stubbe, J., & Lindholt, J. S. Animal Models Used to Explore Abdominal Aortic Aneurysms: A Systematic Review. Eur. J. Vasc. Endovasc. Surg., 2016; 52: 487-499. http://dx.doi.org/10.1016/j.ejvs.2016.07.004
Ijaz, T., Sun, H., Pinchuk, I. V., Milewicz, D. M., Tilton, R. G., & Brasier, A. R. Deletion of nf- b/Rela in Angiotensin ii-Sensitive Mesenchymal Cells Blocks Aortic Vascular Inflammation and Abdominal Aortic Aneurysm Formation. Arterioscler. Thromb. Vasc. Biol., 2017; 37:
-1890.
Li, D., Ma, J., Wang, L., & Xin, S. Apigenin Prevent Abdominal Aortic Aneurysms Formation by Inhibiting the nf- b Signaling Pathway. J. Cardiovasc. Pharmacol., 2020; 75: 229-239.
Neumann, C., Scheffold, A., & Rutz, S. Functions and Regulation of T Cell-derived Interleukin-10. Semin. Immunol., 2019; 44: 101-344.
Zhu, H., Qu, X., Zhang, C., & Yu, Y. Interleukin-10 Promotes Proliferation of Vascular Smooth Muscle Cells by Inhibiting Inflammation in Rabbit Abdominal Aortic Aneurysm. Int. J. Clin. Exp. Pathol., 2019;12: 1260-1271.
Guo, X., Yuan, S., Liu, Y., Zeng, Y., Xie, H., Liu, Z. et al. Serum IgE Levels Are Associated with Coronary Artery Disease Severity. Atherosclerosis, 2016; 251: 355-360. http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.020
Li, J., Deng, Z., Zhang, X., Liu, F., Yang, C., Shi, G. P. Deficiency of Immunoglobulin e Protects Mice from Experimental Abdominal Aortic Aneurysms. faseb J., 2020; 34: 3091-3104.
Marques, F., Priestes, P., Byars, S., Ritchie, S., Wurtz, P., Patel, S. et al. Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-associated Lipocalin [ngal]) in the Development of Cardiac Hypertrophy and Heart Failure. J. Am. Heart Assoc., 2017; 6.
Tarín, C., Fernández-García, C. E., Burillo, E., Pastor-Vargas, C., Llamas-Granda, P., Castejón, B. et al. Lipocalin-2 Deficiency or Blockade Protects against Aortic Abdominal Aneurysm Development in Mice. Cardiovasc. Res.; 111: 262-273.
Serhan, C. N., & Levy, B. D. Resolvins in Inflammation: Emergence of the Pro-resolving Superfamily of Mediators Protection Versus Uncontrolled Inflammation: First Responders and Resolution. J. Clin. Invest., 2018; 128: 2657-2669. http://jci.me/97943/pdf
Pope, N., Salmon, M., Davis, J., Chatterjee, A., Su, G., Conte, M. et al. D-series Resolvins Inhibit Murine Abdominal Aortic Aneurysm Formation and Increase m2 Macrophage Polarization. faseb J., 2016; 30: 4192-4201.
Sousa, M., Abd, A., Stannard, G., & Heather, L. Hypoxia-inducible Factor 1 Signalling, Metabolism and its Therapeutic Potential in Cardiovascular Disease. Biochim. Biophys Acta–Mol. Basis Dis., 2019; 1865: 831-843.
Tsai, S. H., Huang, P. H., Hsu, Y. J., Peng, Y. J., Lee, C. H., Wang, J. C. et al. Inhibition of Hypoxia Inducible Factor-1 Attenuates Abdominal Aortic Aneurysm Progression through the Down-regulation of Matrix Metalloproteinases. Sci. Rep., 2016; 6: 1-11. http://dx.doi.org/10.1038/srep28612
Chen, F., Zhang, Z. D., & Zhu, X. H. Inhibition of Development of Experimental Abdominal Aortic Aneurysm by c-Jun n-Terminal Protein Kinase Inhibitor Combined with Lysyl Oxidase Gene Modified Smooth Muscle Progenitor Cells. Eur. J. Pharmacol., 2015; 766:114-121. http://dx.doi.org/10.1016/j.ejphar.2015.09.046
Motoki, T., Kurobe, H., Hirata, Y., Nakayama, T., Kinoshita, H., Rocco, K. et al. ppar- Agonist Attenuates Inflammation in Aortic Aneurysm Patients. Gen Thorac. Cardiovasc., 2015; 63: 565-571.
Ivanova, E., Myasoedova, V., Melnichenko, A., & Orekhov, A. Peroxisome Proliferator-Activated Receptor (ppar) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis. Curr. Pharm. Des., 2017; 27: 1119-1124.
Nakashiro, S., Matoba, T., Umezu, R. et al. Pioglitazone-incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE -/- Mice.Arterioscler. Thromb. Vasc. Biol., 2016; 36: 491-500.
Klaus, V., Schmies, F., Reeps, C. et al. Cathepsin s is Associated with Degradation of Collagen i in Abdominal Aortic Aneurysm. Vasa, 2018; 47: 285-293.
Lai, C. H., Chang, J. Y., Wang, K. C., Lee, F. T., Wu, H. L., & Cheng, T. L. Pharmacological Inhibition of Cathepsin s Suppresses Abdominal Aortic Aneurysm in Mice. Eur. J. Vasc. Endovasc. Surg., 2020; 59:371-372. https://doi.org/10.1016/j.ejvs.2020.01.008
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Iskra Gissel Camarillo Silerio
This work is licensed under a Creative Commons Attribution 4.0 International License.
